Position in INVA
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$817
+$188 QoQ
Shares Held
36
+33.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#289
of 306 holders
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INVA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Elequin Capital, LP holds $8,088 across 7 Biotechnology names. INVA ranks #5 (10.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NKTR |
Nektar Therapeutics
|
56 | $3,909 | |
| 2 | VRDN |
Viridian Therapeutics, Inc.\DE
|
71 | $1,304 | |
| 3 | ASND |
Ascendis Pharma A/S
|
4 | $1,066 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
16 | $908 | |
| 5 | INVA |
Innoviva, Inc.
This page
|
36 | $817 | |
| 6 | SRPT |
Sarepta Therapeutics, Inc.
|
3 | $53 | |
| 7 | IMCR |
Immunocore Holdings plc
|
1 | $31 |
All Filings in INVA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $817 | 36 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $629 | 27 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,339 | 67 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | $502 | 25 | Shares | Sole | 2025-08-11 | |
| 2024-12-31 | $69 | 4 | Shares | Sole | 2025-02-18 | |
| 2024-09-30 | $9,056 | 469 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $4,739 | 311 | Shares | Sole | 2025-03-11 | |
| 2023-12-31 | $224 | 14 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $259 | 20 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $5,601 | 440 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||